These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
81 related items for PubMed ID: 15990085
1. Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. Liu HB, Hu YS, Medcalf RL, Simpson RW, Dear AE. Biochem Biophys Res Commun; 2005 Aug 19; 334(1):30-7. PubMed ID: 15990085 [Abstract] [Full Text] [Related]
2. PPARγ-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells. Hu Y, Liu HB, Simpson RW, Dear AE. J Endocrinol; 2011 Jan 19; 208(1):R1-7. PubMed ID: 20978184 [Abstract] [Full Text] [Related]
3. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. Liu H, Hu Y, Simpson RW, Dear AE. J Endocrinol; 2008 Jan 19; 196(1):57-65. PubMed ID: 18180317 [Abstract] [Full Text] [Related]
4. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Liang X, Kanjanabuch T, Mao SL, Hao CM, Tang YW, Declerck PJ, Hasty AH, Wasserman DH, Fogo AB, Ma LJ. Am J Physiol Endocrinol Metab; 2006 Jan 19; 290(1):E103-E113. PubMed ID: 16144810 [Abstract] [Full Text] [Related]
5. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, Mizuno K, Fujita T, Tsukamoto K, Watanabe T. Biochem Biophys Res Commun; 1999 May 10; 258(2):431-5. PubMed ID: 10329404 [Abstract] [Full Text] [Related]
6. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, Basolo F, Orlando C, Miccoli P. Endocr Relat Cancer; 2009 Dec 10; 16(4):1299-311. PubMed ID: 19755523 [Abstract] [Full Text] [Related]
7. PPARγ activation induces acute PAI-1 gene expression in the liver but not in adipose tissues of diabetic model mice. Oishi K, Tomita T, Itoh N, Ohkura N. Thromb Res; 2011 Nov 10; 128(5):e81-5. PubMed ID: 21757225 [Abstract] [Full Text] [Related]
8. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. Takeshita Y, Takamura T, Hamaguchi E, Shimizu A, Ota T, Sakurai M, Kaneko S. Metabolism; 2006 Nov 10; 55(11):1464-72. PubMed ID: 17046548 [Abstract] [Full Text] [Related]
10. Identification of a peroxisome proliferator responsive element (PPRE)-like cis-element in mouse plasminogen activator inhibitor-1 gene promoter. Chen JG, Li X, Huang HY, Liu HL, Liu DG, Song TJ, Ma CG, Ma D, Song HY, Tang QQ. Biochem Biophys Res Commun; 2006 Sep 01; 347(3):821-6. PubMed ID: 16843437 [Abstract] [Full Text] [Related]
11. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, Mello T, Ceni E, Varano G, Forti G, Rotondi M, Galli A, Serio M, Luconi M. Arterioscler Thromb Vasc Biol; 2008 Apr 01; 28(4):718-24. PubMed ID: 18239149 [Abstract] [Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells. Ohama Y, Harada T, Iwabe T, Taniguchi F, Takenaka Y, Terakawa N. Fertil Steril; 2008 Feb 01; 89(2):311-7. PubMed ID: 17555752 [Abstract] [Full Text] [Related]
14. Pioglitazone suppresses advanced glycation end product-induced expression of plasminogen activator inhibitor-1 in vascular smooth muscle cells. Yuan X, Liu N. J Genet Genomics; 2011 May 20; 38(5):193-200. PubMed ID: 21621740 [Abstract] [Full Text] [Related]
15. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance. Tencer L, Burgermeister E, Ebert MP, Liscovitch M. Anticancer Res; 2008 May 20; 28(2A):895-906. PubMed ID: 18507034 [Abstract] [Full Text] [Related]
16. Rosiglitazone antagonizes vascular endothelial growth factor signaling and nuclear factor of activated T cells activation in cardiac valve endothelium. Sander TL, Noll L, Klinkner DB, Weihrauch D, He BJ, Kaul S, Zangwill SD, Tweddell JS, Pritchard KA, Oldham KT. Endothelium; 2006 May 20; 13(3):181-90. PubMed ID: 16840174 [Abstract] [Full Text] [Related]
17. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. Liu H, Dear AE, Knudsen LB, Simpson RW. J Endocrinol; 2009 Apr 20; 201(1):59-66. PubMed ID: 19136619 [Abstract] [Full Text] [Related]
18. Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes. Murakami K, Bujo H, Unoki H, Saito Y. Eur J Pharmacol; 2007 Apr 30; 561(1-3):206-13. PubMed ID: 17320860 [Abstract] [Full Text] [Related]
20. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. Lin MS, Chen WC, Bai X, Wang YD. J Dig Dis; 2007 May 30; 8(2):82-8. PubMed ID: 17532820 [Abstract] [Full Text] [Related] Page: [Next] [New Search]